Paper Details

  1. Home
  2. Paper Details

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

Author: FavaM, HusainM M, MiyaharaS, NierenbergA A, RushA J, TrivediM H, WardenD, WisniewskiS R

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study examines the persistence of depressive symptoms in patients with major depressive disorder (MDD) who initially experience improvement with antidepressants. The study focuses on the types and frequency of these residual symptoms and how they relate to the likelihood of relapse after treatment with citalopram, as part of a larger depression study (STAR*D).
Paper Details　
Original Abstract of the Article :
Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/19460188

データ提供：米国国立医学図書館（NLM）

The Shifting Sands of Depression Remission: Residual Symptoms and Relapse

Major depressive disorder (MDD) can be like a deep canyon in the mental landscape. While treatments like antidepressants can help individuals climb out of this canyon, residual symptoms can sometimes persist, creating a risk of relapse. This research explores the prevalence and impact of residual depressive symptoms after remission with citalopram, a commonly prescribed antidepressant.

A Deeper Understanding of Depression

The study found that many patients who experience full symptomatic remission from MDD with citalopram still experience residual depressive symptoms. The researchers also found that the presence of these residual symptoms significantly increased the risk of future depressive relapse. This finding highlights the importance of addressing residual symptoms during treatment to improve long-term outcomes.

Navigating the Terrain of Depression

This research reminds us that the journey towards recovery from depression is often a complex one, like a camel navigating a vast and unforgiving desert. It highlights the importance of addressing all aspects of depression, including residual symptoms, to increase the chances of long-term remission.

Dr.Camel's Conclusion

This research emphasizes that even after experiencing remission from depression, the journey towards recovery is not always straightforward. It's like a camel traversing a desert—even after reaching an oasis, there are still challenges and risks to navigate. This study reminds us that addressing residual symptoms is crucial for ensuring lasting recovery from depression.

Date :
  1. Date Completed 2010-03-01
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

19460188

DOI: Digital Object Identifier

NIHMS225421

Related Literature

Article Analysis
・Effective treatment of depression
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.